Patient Advocacy Groups Rake In Donations From Pharma
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
Drugs
1,161 - 1,180 of 1,300 Results
-
-
Instead Of Trashing A $600 EpiPen, Some Patients Get A Refill
Epinephrine, the active ingredient in EpiPens, expires after 18 months, and the auto-injector device can’t be refilled or reused. Health professionals are looking for work-arounds they say could save the health system millions.
-
President Trump And I Take The Same Drugs — Except One
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
-
Geriatricians Can Help Aging Patients Navigate Multiple Ailments
Aging adults with complex needs can get special assistance from doctors trained as geriatricians.
-
Docs In Northwest Tweak Aid-In-Dying Drugs To Prevent Prolonged Deaths
Some terminal patients, typically high-dose opioid users, who choose to end their lives have taken many hours, even days, to die.
-
Repeal & Replace Watch
Health Law’s 10 Essential Benefits: A Look At What’s At Risk In GOP Overhaul
The woman set to run the federal Centers for Medicare & Medicaid Services told senators last week that maternity coverage should be optional in individual and small group plans. But other services could also be left on the cutting room floor.
-
The Orphan Drug Machine
5 Reasons Why An $89,000 Drug Has Congress Fuming
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
By Sarah Jane Tribble and Sydney Lupkin -
How Long You Stay On Opioids May Depend On The Doctor You See In the ER
A study shows some emergency physicians wrote far more opioid prescriptions and Medicare patients who saw those doctors were more likely to still be taking the addictive painkillers months later.
By Jenny Gold -
Repeal & Replace Watch
Former FDA Chief Cites 5 Things To Watch On Drug Approvals And Keeping Drugs Safe
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
By Sydney Lupkin and Sarah Jane Tribble -
The Orphan Drug Machine
Drugmaker Marathon ‘Pausing’ Delivery Of $89,000-A-Year Muscular Dystrophy Drug
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
By Sarah Jane Tribble and Sydney Lupkin -
Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
-
Treating Cancer: Hope Vs. Hype
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
By Liz Szabo -
Pharmacies Thrive Selling Opioids For Depressed Small Town Pain
Prescription pain pills are strong sellers in this southeastern Kentucky region that’s long struggled with high rates of joblessness and poor health.
-
Drugmaker Kaleo Raises Price Of Lifesaving Drug By Thousands
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
-
The Orphan Drug Machine
KHN Video: Warrior Luke
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
-
Women Fear Drug They Used To Halt Puberty Led To Health Problems
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
-
Prescribing Opioids To Seniors: It’s A Balancing Act
An expert geriatrician says the benefits for the patient, such as alleviating pain and maintaining independence, must be weighed against the possible risks. Her motto: ‘start low and go slow.’
By Jenny Gold -
Trying To Solve The Alzheimer’s Puzzle
Alzheimer's researchers hold onto hope after another promising trial ends in disappointment.
-
Drug Prices, Opioids, And Obamacare: A Conversation With Assemblyman Jim Wood
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
-
Getting Patients Hooked On An Opioid Overdose Antidote, Then Raising The Price
The device, known as Evzio, administers just enough naloxone to stabilize someone who has overdosed on drugs. But its manufacturer, Kaleo, may be positioning itself to find profits in a dire health care crisis.